Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Status:
Withdrawn
Trial end date:
2000-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining interferon alfa or the monoclonal antibody rituximab
with chemotherapy may kill more cancer cells.
PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy plus
interferon alfa or rituximab in treating patients who have high risk stage III or stage IV
lymphoma.